Health Care Technology · Nasdaq

SDGRSchrodinger, Inc.

Last close
$29.53 -4.3%
52-week range
$10.95 to $34.00
Market cap
$1.86B
Next earnings
Not scheduled

Fiscal 2025 at a glance

Revenue
$256M
+23% vs FY24
Net income
-$103M
+45% vs FY24
Free cash flow
$12.5M
+108% vs FY24
Net cash
$395M
Cash $395M, no debt reported

Stock price

-7% since Feb 2020

Valuation vs its own history since 2020

Below its median since 2020 on 1 multiple

Where each multiple sits today inside its own range since 2020, measured at every quarter end. The thin tick is the median.

P/E, trailing
n/a
n/a: No earnings
Median 60.6x, range 49.7x to 190x
Price / sales
6.9x
3.3x61.0x
26th percentile, below its median of 10.4x
EV / EBITDA
n/a
n/a: Not meaningful (negative or missing)
Price / free cash flow
n/a
n/a: Not meaningful (negative or missing)
Median 106x, range 60.6x to 568x

Key statistics

Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.

Valuation

P/E
n/aNo earnings
Earnings yield
-2.7%
Price / sales
6.9x
Price / book
6.2x
Price / operating cash flow
n/a
EV / EBITDA
n/a
EV / sales
5.5x
Free cash flow yield
-6.3%

n/a: Not reported

Profitability

Gross margin
58.5%
Operating margin
-49.6%
Net margin
-22.0%
Return on equity
-19.6%
Return on capital
-35.0%

Growth per year

Revenue, 3 years
+12.2%
Revenue, 5 years
+18.8%
Revenue, 6 years
+20.0%
EPS, 3 years
n/aNot meaningful (a loss in the window)

Balance sheet

Cash and investments
$366M
Total debt
n/a
Net cash
$366M
Debt / equity
n/a
Current ratio
2.75x

n/a: No debt reported

Shares and dividend

Shares outstanding
63.0M
Share count, 5 years
+22.4%
Beta, 1 year
1.63
Dividend yield
n/a
Dividend per share, TTM
n/a
Payout ratio
n/a

n/a: No dividend

Every year we have of the business

Last 31 quarters, fiscal 2019 to 2025 and after. Hover a bar for its quarter.

Revenue and net incomeLatest quarter $64.5M
RevenueNet income
Gross profitLatest quarter $38.3M
EBITDALatest quarter -$24.7M
Margins59 / -41 / -58%
GrossOperatingNet
Earnings per shareLatest quarter -$0.50
Cash flowLatest quarter -$47.6M
OperatingCapexFree
Cash vs debtLatest quarter $366M
Cash and investmentsTotal debt
P/E historyNow n/a
P/E, median 60.6x dashed
P/S historyNow 6.9x
P/S, median 10.4x dashed

Where the revenue comes from

Drug Discovery went from 25% to 22% of revenue in 3 years

Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.

Software Products and ServicesDrug Discovery
FY22
75%25%
$181M
FY23
73%27%
$217M
FY24
87%13%
$208M
FY25
78%22%
$256M
Fiscal 2025 by product line
Product lineRevenueSharevs FY24
Software Products and Services$200M78.0%+11%
Drug Discovery$56.4M22.0%+107%

Health Care Technology peers

The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.

CompanyMarket capRevenue growth Operating marginP/EP/SP/E vs own history
VEEV Veeva Systems Inc $48.8B +16% 29.9%49.4x14.1x 8th percentile
DOCS Doximity, Inc. $5.95B +6% 26.3%46.4x9.0x 36th percentile
WAY Waystar Holding Corp. $5.39B +21% 21.9%40.4x4.3x Not enough history
SDGR Schrodinger, Inc. $1.86B +5% -49.6%No earnings6.9x No earnings

The company

Sector
Health Care
Industry
Health Care Technology
Headquarters
New York, NY
Fiscal year ends
December

Around the numbers

What the rest of EdgeStacker knows about SDGR.

Next report

No confirmed report date in the next 95 days yet.

Open the Earnings Hub
Big funds, latest 13F

Held by 71 active funds. Crowd level: quiet.

Open the Smart money tab